Test Background Mutations in the tyrosine kinase domain of BCR-ABL are the most common cause of resistance to the tyrosine kinase inhibitors (TKI) in CML patients. Therefore, early detection of these mutations will guide clinicians to a more appropriate course of treatment. Sanger sequencing can detect a range of mutations within the TK domain to the level of approximately 20%.
Clinical Indications BCR-ABL1 positive patients that are relapsing or not responding to treatment.
Sample Required 20 mL peripheral blood or 3-5.0 mL bone marrow in EDTA (lavender top); 25uL of cDNA.
Sample Container EDTA (lavender/purple top)
Sample Volume 10ml blood or 1ml bone marrow or 25uL cDNA
Transport/Storage Samples must be less than 72 hours old upon receipt in the lab. PB samples >72 hours old will be rejected.